Can low‑dose naltrexone (LDN) be used to treat persistent fatigue, pain, and cognitive symptoms in a patient who has completed appropriate antibiotic therapy for confirmed Lyme disease?

Low-Dose Naltrexone Should NOT Be Used for Post-Lyme Disease Syndrome

For patients with persistent fatigue, pain, or cognitive symptoms following appropriate antibiotic treatment for confirmed Lyme disease, low-dose naltrexone is not recommended and should not be used. The most recent and authoritative guidelines explicitly address this clinical scenario and provide clear direction against additional pharmacologic interventions beyond standard antibiotic therapy.

Guideline-Based Recommendation

The 2021 IDSA/AAN/ACR Lyme Disease Guidelines provide the definitive answer: patients with persistent nonspecific symptoms (fatigue, pain, cognitive impairment) following recommended treatment for Lyme disease, who lack objective evidence of reinfection or treatment failure, should NOT receive additional antibiotic therapy 1111. This is a strong recommendation with moderate-quality evidence.

The guidelines specify that evidence of persistent infection or treatment failure must include objective signs such as arthritis, meningitis, or neuropathy—not subjective symptoms alone 11.

Why Naltrexone Is Not Appropriate

No Evidence Base for Post-Lyme Disease Syndrome

The 2006 IDSA guidelines established that there is no convincing biologic evidence for symptomatic chronic B. burgdorferi infection after appropriate treatment 22. Controlled trials showed that repeated antibiotic courses provided no benefit for persistent symptoms, with serious adverse events occurring in 7% of patients (including catheter sepsis and anaphylaxis) 2.

Naltrexone Has No Established Role

The FDA-approved indications for naltrexone are limited to alcohol use disorder and opioid dependence 33. Low-dose naltrexone is not approved, studied, or indicated for post-infectious syndromes or Lyme disease.

While recent research has explored LDN for various chronic pain conditions:

• A 2023 randomized controlled trial in arthritis pain found no efficacy for LDN versus placebo 4
• A 2025 meta-analysis in fibromyalgia showed modest pain reduction but with significant heterogeneity 5
• Studies in chronic fatigue syndrome consist only of case reports, not controlled trials 6

None of these conditions are equivalent to post-Lyme disease syndrome, which has a distinct pathophysiology related to post-infectious inflammatory processes rather than ongoing infection 22.

What This Patient Actually Has

This clinical picture represents post-Lyme disease syndrome, defined by 2:

• Documented Lyme disease with appropriate treatment
• Resolution/stabilization of objective manifestations
• Persistent subjective symptoms (fatigue, pain, cognitive complaints) for ≥6 months
• Symptoms causing substantial functional impairment

These symptoms often reflect:

• Slow resolution of inflammatory processes 22
• Coexisting conditions like fibromyalgia (2% population prevalence) 2
• Background symptom rates similar to general population 2

Appropriate Management Approach

Instead of naltrexone or additional antibiotics:

1. Confirm the diagnosis was legitimate: Ensure original Lyme testing was performed by qualified laboratories using validated methods 2

2. Exclude alternative explanations 2:

   • Active coinfections (babesiosis)
   • Fibromyalgia or chronic fatigue syndrome
   • Sleep disorders (sleep apnea)
   • Endocrine disorders (thyroid dysfunction)
   • Psychiatric conditions (depression)
   • Medication side effects

3. Provide symptomatic management:

   • Address pain with standard analgesics (not opioids)
   • Treat sleep disturbances
   • Consider physical therapy
   • Provide psychological support

4. Set realistic expectations: Symptoms typically improve gradually over months 22

Critical Pitfalls to Avoid

• Do not prescribe unproven therapies like LDN that lack evidence for this specific condition
• Do not continue antibiotics beyond standard treatment courses—this increases harm without benefit 2
• Do not validate beliefs in "chronic Lyme infection" when objective evidence is absent 22
• Do not use unvalidated testing (urine antigen tests, blood microscopy) 2

Bottom Line

Low-dose naltrexone has no role in treating post-Lyme disease syndrome. The highest quality, most recent guidelines strongly recommend against additional pharmacologic interventions for persistent subjective symptoms after appropriate Lyme treatment 11. Focus instead on excluding alternative diagnoses, providing symptomatic support, and avoiding potentially harmful interventions that lack evidence.